• en
  • fr
  • An experienced and committed Team

    BOARD OF DIRECTORS

    Mr. Gareau holds P.Eng. and MBA degrees and has 30 years of experience as a serial entrepreneur and senior executive. He was Founder-Chairman, CEO and Managing Director of Ipax Capital, a co-investment fund that completed 32 high-tech acquisitions in eight countries over a 12-year period. Ipax won the title of “Best Performing Private Equity Buyout Fund in the World” with an IRR of 318% compounded (Preqin Study of 20,500 funds since 1984: see www.Preqin.com). Mr. Gareau has owned and managed multiple start-ups valued at several hundreds of millions of dollars, two of which passed the billion-dollar mark. Prior to Ipax, he was the owner and CEO of multiple businesses in the United States, Canada, Europe and Asia, primarily in the fields of high-tech, industrial computer components, medical software and communications satellites.

    A former Premier of Québec, Leader of the Opposition in the House of Commons of Canada, Secretary of State and Cabinet Minister in the Canadian government and Ambassador to France, Mr. Bouchard is widely respected for his skill in bringing disparate viewpoints to the table. He is a well-known lawyer and diplomat in the world of international affairs. Mr. Bouchard is Member of the Queen’s Privy Council for Canada, Commandeur de la Légion d’honneur Française and received the Grand Officier de l’Ordre National du Québec (G.O.Q.) in 2008 and the Queen Elizabeth II Diamond Jubilee Medal in 2012. He holds a Doctorate Honoris Causa from Université de Montréal, a second one from l’Université Lumière de Lyon and a third one from Université du Québec à Chicoutimi (UQAC).

    Mr. Gouin holds a B.A. and an MBA from the Ivey School of Business of the University of Western in Ontario. He is currently Chairman of the Anges Québec Capital Fund and an independent member of the board of Onex, a Private Equity Firm with $32 Billion under management. He recently retired as Chairman of the Board of Quebecor Media Inc., a communications and media-cable and entertainment company. He is also the former Advisory Director of Citigroup Global Markets Canada Inc. (1998–2003), former President and Chief Operating Officer of Le Groupe Vidéotron Ltée. (1991-1996) and former Chairman of the Board of TVA Group Inc. He previously served on the Advisory Committee of the Richard Ivey School of Business at the University of Western Ontario for over 20 years.

    Mr. Monette graduated magna cum laude as a chemical engineer from Polytechnique Montréal and received a diploma in advanced management from Harvard University. He was President and CEO of Johnson & Johnson France, then became President and CEO of Janssen Pharmaceutical in Toronto. He has acted as President of the governance committee at the R.E. Fund of Fonds de Solidarité des Travailleurs du Québec (FSTQ) and served as a member of the board of several institutions including Investissement-Québec and the Real Estate Fund of the FSTQ. He has served as a member of the investment committee of several institutions including the New Economy of the FSTQ and Amorchem, an institutional Life Science investment fund.

    Mr. Dozois, LL.L. MBA, joined BCF as a partner in 1997 to lead its commercial law practice and to co-head the firm’s Securities Group. Having the benefit of more than 40 years of experience in several business law fields, his current practice is primarily focused on mergers and acquisitions and on public and private financing. Mr. Dozois has served on a great number of boards of directors of corporations as well as non-profit and charitable organizations. He is a past director and president of the prestigious Club St-Denis de Montréal and of Fondation de l’Hôpital Notre-Dame de Montréal. He is now a director and member of the Executive Committee of Fondation du Centre hospitalier universitaire de Montréal (CHUM).

    ADMINISTRATION

    Mr. Gareau holds P.Eng. and MBA degrees and has 30 years of experience as a serial entrepreneur and senior executive. He was Founder-Chairman, CEO and Managing Director of Ipax Capital, a co-investment fund that completed 32 high-tech acquisitions in eight countries over a 12-year period. Ipax won the title of “Best Performing Private Equity Buyout Fund in the World” with an IRR of 318% compounded (Preqin Study of 20,500 funds since 1984: see www.Preqin.com). Mr. Gareau has owned and managed multiple start-ups valued at several hundreds of millions of dollars, two of which passed the billion-dollar mark. Prior to Ipax, he was the owner and CEO of multiple businesses in the United States, Canada, Europe and Asia, primarily in the fields of high-tech, industrial computer components, medical software and communications satellites.

    Mr. Heinzelmann holds an MBA from Rochester and a Diploma in Professional Coaching from Zurich Switzeland and has over 25 years of experience as a senior executive, with a wealth of specialized experience in international business. Recently, Mr. Heinzelmann was Vice President Finance and a managing Partner of Ipax Capital. Prior to Ipax, he started his career with Buhler, a $2 Billion technology partner and specialist in equipment and related services for processing basic foods. Following a transfer to Casablanca, Morocco, he was given responsibility for all commercial activities of the Moroccan subsidiary. After Bulher, he worked several years for Sulzer, a $6 Billion Swiss international equipment manufacturer for the energy and transportation industries, as head of Corporate Reporting, with 300 entities around the world to be consolidated. He was also a member of the deal teams in charge of acquisitions and divestitures, where he assumed responsibility for all financial aspects of investment transactions. Fred brings an extensive knowledge and experience of corporate finance and Reporting and top manager coaching. He is fluent in German, English and French.

    Mr. Monette graduated magna cum laude as a chemical engineer from Polytechnique Montréal and received a diploma in advanced management from Harvard University. He was President and CEO of Johnson & Johnson France, then became President and CEO of Janssen Pharmaceutical in Toronto. He has acted as President of the governance committee at the R.E. Fund of Fonds de Solidarité des Travailleurs du Québec (FSTQ) and served as a member of the board of several institutions including Investissement-Québec and the Real Estate Fund of the FSTQ. He has served as a member of the investment committee of several institutions including the New Economy of the FSTQ and Amorchem, an institutional Life Science investment fund.

    Thierry holds a Chemical Engineering degree from Polytechnique Montréal (Canada) with graduate studies in applied sciences at the Université Catholique de Louvain (Belgium) and in Management at MIT Sloan, Cambridge (USA). Thierry is a seasoned executive with a successful track record in entrepreneurial management, technology development, commercialization and licensing, company operations, intellectual property, lean management and financing in several industries including high tech and health technologies. Before joining Starpax Medical, Mr. Pagé held a number of senior positions, including that of founding CEO at Odotech Inc and Senior Director, Sciences & Engineering at Univalor (the Technology Transfer Office of Université de Montreal, Polytechnique Montréal, HEC and 6 affiliated research hospitals)

    SCIENTIFIC ADVISORS

    Dr. Martel holds a Post-Doctorate from the Massachusetts Institute of Technology (MIT) and a Ph.D. in Electrical/Biomedical Engineering from the Polytechnique Montréal.
    Over the years of his distinguished career, he has earned many titles including the Canada Research Chair (CRC, Government of Canada) Tier 1 in Medical Nano-robotics and the Chair of the IEEE Technical Committee on Micro-Nano-robotics and Automation. He was also a Former Lieutenant-commander and Warship Commanding Officer– Canadian Armed Forces (Navy – Reserve).

    Dr. Martel’s academic honours include the Queen Elizabeth II Diamond Jubilee Medal for excellence in scientific contributions and realizations; the La Presse and Radio-Canada Personality of the Week (twice); the Jean-Jacques Rousseau Prize for Interdisciplinary Research; the Top Recipient award from the National Science and Research Council of Canada; the Innovator of the Year Award (life sciences and health technology) given by Montréal InVivo; the Dr. Jean-A. Vézina Prize for Innovation and Excellence from the Société canadienne-française de radiologie (honorary member); and he was named Personality of the Month by the Fédération de l’informatique (FiQ).

    Dr. Martel is responsible for scientific research, engineering and nano-robotics at Starpax Medical and is the inventor of the Magnetotaxi, which is currently under exclusive rights to Starpax Medical. Dr. Martel has been published in over 100 prestigious scientific journals and magazines and has given over 200 conferences throughout the world on electromagnetism, bioengineering, nano-robotics and bio-medical engineering

    ONCOLOGY TEAM - CLINICAL TESTS

    Education:
    Post-doctorate, New York, Boston and National Cancer Institute of Washington, in medical oncology and molecular pharmacology, Ph.D Medicine, McGill
    Positions:
    • Director, Segal Cancer Centre
    • Director, Dept. of Oncology, Sir Mortimer B. Davis-Jewish General Hospital Scientific
    • Director, Montreal Centre for Experimental Therapeutics in Cancer Director, McGill University, Centre for Translational Research in Cancer
    • Chair, Department of Oncology, McGill University
    • Professor, Department Medicine and Oncology, McGill University
    Co-founder:
    Consortium de recherche en oncologie du Québec (Q-CROC) Internship/Residency: St. Vincent’s Hospital Centre, New York City, NY New England Deaconess Hospital, Boston, MA
    Publications:
    More than 180 publications in medical and scientific journals
    Profile:
    Dr. Batist has been deeply involved in the project for several years. His wealth of experience in clinical trials and approval processes with the FDA and Health Canada and his internationally renowned experience in oncology and chemotherapy are precious assets for Starpax.
    Education:
    Ph.D Medicine, Oncology, Université de Montréal
    Positions:
    • Director of the Segal Cancer Center’s Radiation Oncology
    • Chief of radiation oncology, Montreal Jewish Hospital
    • Associate Member, Department of Medicine, Division of Experimental Medicine, Mc Gill University
    Internship/Residency:
    • Université de Montréal and University of Toronto
    • Université de Paris
    Publications:
    More than 50 publications in peer-reviewed medical journals
    Profile:
    For the past six years, Dr. Vuong has participated in the development of the Starpax technology as specialist in oncology. She is a strong believer in the benefits of Starpax and as such, is very active in the preparation of the human clinical trials and Medical Vector approvals by the FDA and Health Canada.
    Education:
    • Post-Ph.D., Molecular Immuno regulation, NIH, NCI, FCRF, Maryland, USA
    • Ph.D., Molecular Biology, Oncology, Crawco l University
    Positions:
    • Professor, Human Genetics, at the Doctorate level, McGill University
    • External Reviewer Medical Research Council of Canada, 1990-1999
    • Review Board Medical Research Council of Canada 1994-1995
    • Academic Advisor for a Department of Medicine
    • External Reviewer for CIHR (Canadian Institutes of Health Research)
    • Internal Reviewer – McGill University Health Centre Foundation
    • National Center of Excellence (NCE) AllerGen: Advanced Education and Training Opportunities (AETOAC) Advisory Committee
    • Internal Reviewer Canadian Institute of Health Research – Postdoctoral Scholarships Awards Committee
    Publications:
    More than 50 publications in Medical and Scientific journals

    SCIENCE & DEVELOPMENT

    Education:

    Ph.D in microbiology and molecular genetics, Laval University

    For the past 12 years, Dr. Mohammadi has been working on the predecessor of the Bn1 bacterial transporter, now owned by Starpax Medical. He created in laboratory after numerous controlled mutations the first steerable, self-propelled, magneto-tactic, bacterial nano-transporter for the specific use of the Starpax technology. Dr. Mohammadi is a world expert on the integration of magneto tactic bacteria as bio-actuators and controllable nano-self-propulsion systems for critical applications such as tumor targeting for enhanced therapeutic effects in cancer therapy. He has been cited more than 100 times in specialized scientific journals, documentaries and TV interviews, and contributed to more than 50 scientific papers on the subject.

    Education:
    • M.Sc., Biomedical Engineering, Montréal Polytechnique
    • M.Sc., Electrical Engineering, University of Moldova
    • B.Sc., Computer Engineering, Montréal Polytechnique

    For the past five years, Mr. Loghin has taught computer architecture, medical robotics and procedural programming of robots at the Polytechnique Montreal, all while directing the development of the control software for the Starpax Magnetotaxi. Prior to that, he worked in the software departments at Procetrix and RelSoft for ten years years.

    Education:
    • Master in Bioethics, University of Montreal
    • Bachelor in Engineering physics, Montréal Polytechnique
    Mr. Tremblay has been in charge of all aspects of ethical research for the nano-transporter project for the past ten years. He has worked as project manager and manager/coordinator of the nano-robotics laboratories and acquired several years of experience as Director of Bio-ethics, coordinating medical doctors, scientists, engineers, administrative representatives of government health authorities while working on clinical test protocols.